283 related articles for article (PubMed ID: 24507789)
1. Soluble ST2 and galectin-3 in heart failure.
Shah RV; Januzzi JL
Clin Lab Med; 2014 Mar; 34(1):87-97, vi-vii. PubMed ID: 24507789
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
3. State of the Art: Newer biomarkers in heart failure.
de Boer RA; Daniels LB; Maisel AS; Januzzi JL
Eur J Heart Fail; 2015 Jun; 17(6):559-69. PubMed ID: 25880523
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.
Karayannis G; Triposkiadis F; Skoularigis J; Georgoulias P; Butler J; Giamouzis G
Curr Heart Fail Rep; 2013 Dec; 10(4):441-9. PubMed ID: 24142671
[TBL] [Abstract][Full Text] [Related]
5. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results.
Wu AH; Wians F; Jaffe A
Am Heart J; 2013 Jun; 165(6):995-9. PubMed ID: 23708172
[TBL] [Abstract][Full Text] [Related]
6. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.
Gruson D; Ferracin B; Ahn SA; Rousseau MF
Int J Cardiol; 2015 Jun; 189():185-7. PubMed ID: 25897901
[No Abstract] [Full Text] [Related]
8. Soluble ST2 in heart failure.
Dieplinger B; Mueller T
Clin Chim Acta; 2015 Mar; 443():57-70. PubMed ID: 25269091
[TBL] [Abstract][Full Text] [Related]
9. ST2 and patient prognosis in chronic heart failure.
Bayes-Genis A; Zhang Y; Ky B
Am J Cardiol; 2015 Apr; 115(7 Suppl):64B-9B. PubMed ID: 25665758
[TBL] [Abstract][Full Text] [Related]
10. Novel biomarkers in heart failure with preserved ejection fraction.
Shah KS; Maisel AS
Heart Fail Clin; 2014 Jul; 10(3):471-9. PubMed ID: 24975910
[TBL] [Abstract][Full Text] [Related]
11. Soluble ST2 and galectin-3 in pediatric patients without heart failure.
Meeusen JW; Johnson JN; Gray A; Wendt P; Jefferies JL; Jaffe AS; Donato LJ; Saenger AK
Clin Biochem; 2015 Dec; 48(18):1337-40. PubMed ID: 26277636
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure.
Zhang R; Zhang Y; An T; Guo X; Yin S; Wang Y; Januzzi JL; Cappola TP; Zhang J
Biomark Med; 2015; 9(5):433-41. PubMed ID: 25985174
[TBL] [Abstract][Full Text] [Related]
13. Can biomarkers help to diagnose early heart failure with preserved ejection fraction?
Meluzín J; Tomandl J
Dis Markers; 2015; 2015():426045. PubMed ID: 25802475
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
[TBL] [Abstract][Full Text] [Related]
15. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
16. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of novel biomarkers in heart failure: towards personalized medicine.
Schmitter D; Cotter G; Voors AA
Heart Fail Rev; 2014 May; 19(3):369-81. PubMed ID: 23709316
[TBL] [Abstract][Full Text] [Related]
18. Soluble ST2 in Ventricular Dysfunction.
Lupu S; Agoston-Coldea L
Adv Clin Chem; 2015; 69():139-59. PubMed ID: 25934361
[TBL] [Abstract][Full Text] [Related]
19. ST2 pathogenetic profile in ambulatory heart failure patients.
Bayes-Genis A; Januzzi JL; Gaggin HK; de Antonio M; Motiwala SR; Zamora E; Galán A; Domingo M; Urrutia A; Lupón J
J Card Fail; 2015 Apr; 21(4):355-61. PubMed ID: 25451702
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in acute heart failure.
Mallick A; Januzzi JL
Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):514-25. PubMed ID: 25911167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
